Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- Enspryng (satralizumab)
- ifosfamide
Interactions between your drugs
ifosfamide satralizumab
Applies to: ifosfamide, Enspryng (satralizumab)
Satralizumab may decrease the blood levels and effects of ifosfamide. You may need a dose adjustment if you have been receiving ifosfamide and are starting treatment with satralizumab. Likewise, if you have been receiving both medications, the dose of ifosfamide may need to be adjusted when satralizumab is discontinued. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
ifosfamide food
Applies to: ifosfamide
Do not consume grapefruit or grapefruit juice while you are receiving treatment with ifosfamide, as this may decrease the anticancer effects of ifosfamide and may increase its adverse effects on your nervous system and your kidneys. Do not use alcohol while you are receiving treatment with ifosfamide. This may increase nervous system side effects such as somnolence, dizziness, confusion, difficulty concentrating, and impairment of thinking and judgment; and may also increase nausea and vomiting. Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed. Also, avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medication without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Uplizna
Uplizna is used to treat adults with neuromyelitis optica spectrum disorder (NMOSD) or ...
Ultomiris
Ultomiris (ravulizumab-cwvz) is used for the treatment of myasthenia gravis, paroxysmal nocturnal ...
Soliris
Soliris infusion is used to treat paroxysmal nocturnal hemoglobinuria (PNH) or neuromyelitis optica ...
Bkemv
Bkemv (eculizumab-aeeb) is an interchangeable biosimilar to Soliris which may be used to treat ...
Epysqli
Epysqli (eculizumab-aagh), a biosimilar to Soliris, targets the complement system to treat ...
Inebilizumab
Inebilizumab is used to treat adults with NMOSD (neuromyelitis optica spectrum disorder) who are ...
Ravulizumab
Ravulizumab-cwvz is used to treat myasthenia gravis (gMG), hemolytic uremic syndrome (aHUS) ...
Eculizumab
Eculizumab (brand names Soliris, Bkemv, and Epysqli) is used to treat paroxysmal nocturnal ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.